DV
Dividend Vision

ELDN — Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. (ELDN)

Total return is -99.9% over the past 11.9 years, 472.9 points behind SPY at 373.0%. Its deepest 1-year drawdown was 68.1%.

Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immunology therapies that target the CD40 ligand pathway to prevent transplant rejection. As an early-stage biotech equity, the company does not currently pay distributions and carries typical risks associated with pre-revenue pharmaceutical development, including regulatory and clinical trial uncertainties. This security appeals primarily to investors with high risk tolerance seeking exposure to innovative immunology research rather than current income generation.

ELDN key facts

Asset type
Stock
Asset class
Equity
Inception date
09/17/2014
Last close
$3.54
Market cap
$287,664,480
Average volume
1341600.0
Payment date
10/05/2020
Beta
0.956
Payout ratio
0.0
Forward P/E
5.3908
EPS
$-0.86